Bioversys AG (SW:BIOV) — Market Cap & Net Worth
Market Cap & Net Worth: Bioversys AG (BIOV)
Bioversys AG (SW:BIOV) has a market capitalization of $161.41 Million (CHF127.67 Million) as of June 19, 2026. Listed on the SW stock exchange, this Switzerland-based company holds position #17461 globally and #176 in its home market, demonstrating a -1.11% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bioversys AG's stock price CHF26.70 by its total outstanding shares 5848011 (5.85 Million). Review Bioversys AG debt and liabilities to assess the company's total debt and financial obligations.
Bioversys AG Market Cap History: 2025 to 2026
Bioversys AG's market capitalization history from 2025 to 2026. Data shows growth from $180.40 Million to $197.41 Million (0.00% CAGR).
Bioversys AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bioversys AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
225.50x
Bioversys AG's market cap is 225.50 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $180.40 Million | $800.00K | -$21.83 Million | 225.50x | N/A |
Competitor Companies of BIOV by Market Capitalization
Companies near Bioversys AG in the global market cap rankings as of June 19, 2026.
Key companies related to Bioversys AG by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
Bioversys AG Historical Marketcap From 2025 to 2026
Between 2025 and today, Bioversys AG's market cap moved from $180.40 Million to $ 197.41 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CHF197.41 Million | +9.43% |
| 2025 | CHF180.40 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Bioversys AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $161.41 Million USD |
| MoneyControl | $161.41 Million USD |
| MarketWatch | $161.41 Million USD |
| marketcap.company | $161.41 Million USD |
| Reuters | $161.41 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bioversys AG
BioVersys AG researches and develops antimicrobial drugs for bacterial infections. It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections. The company is also developing Alpibectir, which is in Phase 2 clinical trial for the treatment of pulmonary and meningeal tuberculosis; BV200 to treat patients with Gram-positive S.… Read more